3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Leukemia
1
Interventions
Cytarabine
116
Cyclophosphamide
104
venetoclax
89
fludarabine
85
Azacitidine
81
fludarabine phosphate
70
Rituximab
59
Filgrastim
44
Peripheral Blood Stem Cell Transplantation
39
Methotrexate
39
Dexamethasone
35
Decitabine
35
Busulfan
32
Etoposide
31
Tacrolimus
30
Mycophenolic Acid
29
Granulocyte Colony-Stimulating Factor
28
Lenalidomide
27
Whole-Body Irradiation
26
Idarubicin
26
Vincristine
25
Melphalan
24
Cyclosporine
24
Clofarabine
24
Mitoxantrone
22
Bortezomib
21
Alemtuzumab
21
ibrutinib
19
ruxolitinib
17
aldesleukin
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Cobicistat
×
Other hematologic neoplasm
×
Clear all
NCT04065399
2026-03-18
AUGMENT-101
Syndax Pharmaceuticals
Phase 1/2
Recruiting
447 enrolled
2 FDA